Loading...
Loading...
PBYI| Name | Value |
|---|---|
| Revenues | 59.1M |
| Cost of Revenue | 13.9M |
| Gross Profit | 45.2M |
| Operating Expense | 31.8M |
| Operating I/L | 13.4M |
| Other Income/Expense | -1.1M |
| Interest Income | 1.2M |
| Pretax | 12.2M |
| Income Tax Expense | -7.1M |
| Net Income/Loss | 19.3M |
Puma Biotechnology, Inc. is a biopharmaceutical company specializing in the development and commercialization of cancer care products. Its drug candidates include PB272 neratinib for early stage HER2-overexpressed/amplified breast cancer, as well as for advanced or metastatic HER2-positive breast cancer and HER2 mutation-positive solid tumors. The company generates revenue through the development and commercialization of these drug candidates, as well as through license and sub-license agreements with various pharmaceutical companies for the distribution and marketing of its products.
